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Abstract
Background Transanal total mesorectal excision (TaTME)
has rapidly become an important component of the treat-
ment of rectal cancer surgery. Cohort studies have shown
feasibility concerning procedure, specimen quality and
morbidity. However, concerns exist about quality of life
and ano(neo)rectal function. The aim of this study was to
prospectively evaluate quality of life in patients following
TaTME for rectal cancer with anastomosis.
Methods Consecutive patients who underwent restorative
TaTME surgery for rectal adenocarcinoma in an academic
teaching center with tertiary referral function were evalu-
ated. Validated questionnaires were prospectively col-
lected. Quality of life was assessed by the EuroQol 5D
(EQ-5D), European Organization for Research and Treat-
ment of Cancer’s QLQ-C30 and QLQ-CR29 and low
anterior resection syndrome (LARS) scale. Outcomes of
the questionnaires at 1 and 6 months were compared with
preoperative (baseline) values.
Results Thirty patients after restorative TaTME for rectal
cancer were included. Deterioration for all domains was
mainly observed at 1 month after surgery compared to
baseline, but most outcomes had returned to baseline at
6 months. Social function and anal pain remained signifi-
cantly worse at 6 months. Major LARS (score [30) was
33% at 6 months after ileostomy closure. No end colos-
tomies were required.
Conclusions TaTME is associated with acceptable quality
of life and functional outcome at 6 months after surgery
comparable to published results after conventional laparo-
scopic low anterior resection.
Keywords Rectum  Cancer  Surgery  TaTME  Quality
of life  PROMs
Introduction
The transanal total mesorectal excision (TaTME) technique
for mid- and low rectal cancer has raised great interest
worldwide. Available data from cohort studies suggest that
TaTME is a feasible and safe technique [1–4]. The overall
morbidity, specimen quality and margins appear to be
comparable to conventional low anterior resection, while
high-quality data from randomized studies are still lacking
[5–7]. Moreover, long-term outcome is still unknown.
The transanal approach enhances visualization of the
surgical planes in the mid- and low mesorectum, allowing
more careful dissection compared to conventional TME.
Potential advantages of the TaTME technique are less
morbidity, less conversions to open or Hartmann’s proce-
dure and more sphincter saving procedures. However,
concerns exist whether the TaTME technique hampers
functional outcome compared to conventional low anterior
resection. First, the level of anastomosis in TaTME is
potentially created closer to the anal sphincter compared to
conventional laparoscopic TME. Secondly, the TaTME
technique could result in damage to the sphincter caused by
prolonged dilatation of the anal canal. At last, in TaTME,
the resection could be more radical in the lower pelvis,
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especially within the learning phase, which could be
associated with collateral damage to the innervation of the
levator ani muscle. Currently, data on quality of life and
ano(neo)rectal function after TaTME are scarce [8–12].
The published studies have used a variety of scores and
methods to define and compare fecal incontinence, urinary
and sexual dysfunction. These studies also lack comparison
with preoperative baseline values.
To our knowledge, this study is the first to present
prospectively reported quality of life of patients undergo-
ing TaTME low anterior resection for rectal cancer using
validated questionnaires.
Materials and methods
VU University Medical Center in Amsterdam is an aca-
demic teaching hospital with a tertiary referral function
for patients with rectal cancer. Patients presented with
rectal cancer in the VU University Medical Center
between January 2014 and January 2016 and operated on
using TaTME with construction of a primary anastomosis
after resection were included. Preoperative work-up
including imaging and neoadjuvant treatment was orga-
nized according to the Dutch National Guidelines for
Rectal Cancer, and postoperative care according to
Enhanced Recovery after Surgery (ERAS) guidelines. The
technique used has been described in an earlier article. An
ileostomy was created when deemed necessary by the
treating surgeon, and after 6 weeks the anastomosis was
evaluated by a computed tomography (CT) scan with
contrast enema and under direct visualization using sig-
moidoscopy. After excluding anastomotic problems, the
stoma was reversed. Only patients with good preoperative
sphincter function were selected for low anastomosis,
assessed by history taking, digital examination and addi-
tional manometry when the treating surgeon judged
objective confirmation of the function was needed. All
patients undergoing abdominoperineal resection (APR),
operations for benign disease or follow-up less than
6 months were excluded. This study was approved by the
Institutional Review Board of VU University Medical
Center.
Baseline data
Baseline characteristics such as gender, age, body mass
index (BMI), neoadjuvant treatment, clinical American
Joint Committee on Cancer (AJCC) stage were prospec-
tively collected from patient records. Operative and post-
operative data included type of anastomosis, creation of
diverting ileostomy, type of specimen extraction, length of
hospital stay, and complications during and after surgery
including bleeding, technical problems, urinary retention,
anastomotic leakage (definition according to Rahbari et al.
[13]) diagnosed on CT scan, coloanal stenosis needing
dilatation, and stoma-related problems. Regarding pathol-
ogy outcomes, AJCC stage, quality of specimen (using
Quirke’s classification [14]), circumferential mesorectal
margin (CRM) involvement, total number of lymph nodes
harvested, tumor diameter, and radicality were collected.
During follow-up, the following data were collected: time
to local recurrence defined as tumor found near the anas-
tomosis, time to distant recurrence defined as metastasis in
other organ(s) and survival. Follow-up was organized
according to the Dutch National Guidelines for Colorectal
Cancer.
Questionnaires
Patient-reported outcome measurements were collected
prospectively by sending questionnaires within 1 week
before surgery and 1 and 6 months after surgery. The fol-
lowing questionnaires were used: EuroQol with five
dimensions (EQ-5D-3L), European Organization for
Research and Treatment of Cancer (EORTC) QLQ-CR29
and QLQ-C30, version 3.0, and low anterior resection
syndrome (LARS).
The EQ-5D-3L questionnaire was used to evaluate the
level of mobility, self-care, activity, pain, and anxiety. The
EQ-5D index was calculated for overall scoring and the
EQ-VAS [a visual analogue scale from 0 (worst) to 100
(best)] was used to asses patients’ global health.
The EORCT QLQ-CR29 module was analyzed using 4
multi-item scales including body image (items 45, 46 and
47), micturition scale (items 31 and 32), blood and mucus
in stool (items 38 and 39), frequency of bowel movement
(items 52 and 53) and 19 single items according to modi-
fications by Whistance et al. [15].
For the EORCT QLQ-C30 module scoring procedures
were used as described in the EORTC scoring manual
QLQ-C30, version 3.0 [16]. The QLQ-C30 is composed of
5 functional scales, 3 symptom scales, a global health
status and 6 single items.
The QLQ-CR29 and QLQ-C30 were converted to a
score ranging from 0 to 100 in order to compare means.
Changes in QLQ-C29 and CR30 were interpreted to be
small, moderate and substantial if difference in mean
scores was 5–10, 10–20 and greater than 20, respectively
[17].
To evaluate the ano(neo)rectal function after TaTME,
the LARS questionnaire was used. In case of an ileostomy,
the questionnaire was sent 1 and 6 months after stoma
closure (Fig. 1). The LARS score was categorized into no
LARS (0–20 points), minor LARS (21–29 points), and
major LARS (30–42 points) [18].
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Statistical analysis
Repeated measures analysis of variance (ANOVA) was
used to investigate changes in mean questionnaire scores
between 3 time points. In case Mauchly’s Test of
sphericity was violated, we used the Greenhouse-Geisser
correction when the estimate of sphericity (e) was \0.75
and the Huynh–Feldt correction when e was[0.75. If the
effect was significant, post hoc testing using the Bonfer-
roni correction was performed in order to specify the
statistical significant difference between the measurement
moments. A p value B0.05 was considered statistically
significant. Statistical analysis was done using SPSS
version 23 for Windows and Mac (SPSS, Chicago, Illi-
nois, USA).
Results
Between January 2014 and February 2016, 140 patients
underwent rectal resection at VU University Medical
Center. Seventy-one of these patients underwent elective
resection with curative intent for rectal cancer. The other
patients underwent resection for benign or metastasized
disease. Thirty consecutive patients undergoing TaTME
with a primary anastomosis were included for prospective
collection of questionnaires. The 30 patients (21 males,
70%) had a median age of 65 years (interquartile range
(IQR) 58–69 years), the mean BMI was 26 kg/m2 (IQR
24–28 kg/m2) and 27 (90%) patients were categorized as
American Society of Anesthesiologists (ASA) class I–II,
(Table 1). Median tumor distance from the anal verge on
magnetic resonance imaging (MRI) was 6 cm (IQR
4–8 cm). Twenty-two patients (73%) received neoadjuvant
treatment; 12 patients (40%) short course radiotherapy and
10 patients (33%) long course chemoradiotherapy. One
patient had salvage TaTME for a local regrowth during
wait and see policy after initial complete response on
neoadjuvant therapy. Three patients underwent completion
TaTME after local excision of the primary tumor.
No deviating stoma 
n = 5
After SC 
n = 10
Excluded 
1. No SC, n = 10 
2. After SC but follow-up < 6 
months  n = 5
No 6-month response 
Deceased n = 1 
Nonresponder n = 1 
Preop, 1 month and 6 months: 
General questions 
EQ-5D, QLQ-CR29, QLQ-C30 
n = 28
Preop, 1 month and 6 months: 
LARS 
n = 15
I
II
Eligible for inclusion 
n = 30
Fig. 1 Overview included
patients in the general analysis
(I) and ano(neo)rectal function
(II). SC stoma closure, LARS
low anterior resection syndrome
Table 1 Patient and tumor characteristics
Age (median, SD, years) 66 (9.3)
Male 21 (70%)
Body mass index (median, SD, kg/m2) 26.4 (3.8)
Tumor height from anal verge (median, IQR, cm) 6.0 (4.0–8.0)
AJCC stage
0 4 (13)
I 11 (37)
II 6 (20)
III 7 (23)
IV 2 (7)
Neoadjuvant therapy 22 (73)
Radiotherapy only 12 (40)
Chemoradiotherapy 10 (33)
No diverting ileostomy at index surgery 6 (20)
Male, neoadjuvant therapy, AJCC stage and ileostomy are presented
as frequency with percentage
SD standard deviation, IQR interquartile range, AJCC American Joint
Committee on Cancer
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At the time of analysis, 15 of the 25 diverting ileos-
tomies were reversed, and the median period after primary
surgery was 4 months (IQR 3–5 months). Median follow-
up after reversal was 11 months (IQR 5–16 months).
Stoma was not reversed due to a chronic presacral sinus in
the 3 patients, metastatic disease in 1 patient needing
adjuvant chemotherapy, preference to wait before under-
going another operation after an earlier correction of the
stoma in one patient, and death at 7 months after removal
of the rectum in 1 patient. At the time of analysis, reversal
had been planned for 4 patients.
Response rate
The response rate at 6 months was 93% for the general
population (n = 28) and 100% for the population analyzed
after stoma closure (n = 15). One patient died at 7 months
and another patient was unwilling to fill out the last
questionnaire, therefore, no 6-month questionnaires were
received from these patients.
Operative details
All included patients received primary anastomosis, per-
formed by circular stapler in 17 patients (57%) and hand
sewn in 13 patients (43%). In 67% of the patients, an end-
to-end anastomosis was made. In 24 patients (80%), the
surgeon decided to create a primary deviating ileostomy.
Intraoperative complications included a case of bleeding
not requiring blood transfusion and one incomplete donut
after stapling requiring a circular hand sewn anastomosis.
Specimen retrieval was done through a Pfannenstiel inci-
sion (60%), trocar/stoma site (7%) or transanally (33%).
There were no conversions.
Pathology
All specimens (100%) were R0, defined as no tumor tissue
within 1 mm of the resection margins. One specimen was
judged incomplete (3.3%). Positive lymph nodes were
found in 7 (23%) patients. The mean number of harvested
lymph nodes was 15 (IQR 9–18). Stage according to the
AJCC is shown in Table 1.
Postoperative outcome
Overall 30-day morbidity was 36.7% including major
morbidity (Clavien–Dindo grade CIII) in 17% of the
patients. Two patients (7%) developed anastomotic leakage
requiring reoperation. One of these patients already had a
diverting ileostomy. Two patients had a presacral abscess
for which CT guided drainage was performed. Both
patients already had a diverting ileostomy. Stoma-related
problems included high output ileostomy (21%) requiring
medication and passage problems (8%) requiring re-inter-
vention. Three patients needed temporary catheterization
for urinary retention. Median hospital stay was 7 days
(IQR 6–10 days).
Long-term outcome
Median follow-up duration was 14 months (IQR
8–19 months). No local recurrence was observed during
follow-up. Distant metastases were found in 5 patients
(17%) with a median interval of 185 days (IQR
62–239 days) after initial surgery. In 3 patients, liver
metastases were treated with radical resection or radio-
frequency ablation (RFA). In 1 patient, treated for local
recurrence after wait and see policy for a complete
response failed, palliative treatment was started when
widespread pulmonary, para-aortal, and peritoneal metas-
tases were observed. One patient developed brain metas-
tases and died 7 months postoperatively.
Overall quality of life (EQ-5D-3L)
The preoperative mean score of the EQ-5D index was 90.2
(95% CI 83.9–96.5). After 1 month a significant decrease
was observed to 78.2 (95% CI 68.9–87.4), (p = 0.031),
and after 6 months, the EQ-5D returned near to preopera-
tive score, 86.0 (95% CI 79.9–92.2). Subanalysis of the
domains showed a significant increase in problems expe-
rienced in social life (p = 0.015) at 1 month, but this
significant difference disappeared after 6 months. The
other domains were not significantly influenced by the
operation (Table 2). Analyzing the EQ-VAS for pain, a
significant aggravation was observed 1 month after surgery
(p = 0.008), but the VAS scores were similar to the other
scores after 6 months when no significant difference was
found compared to baseline (p = 0.351).
Colorectal cancer specific quality of life (EORTC
QLQ-C30 and QLQ-CR29)
Significant drop in scores was observed at 1 month after
surgery for quality of life (p = 0.012), physical functioning
(p = 0.001), role functioning (p\ 0.001), fatigue
(p = 0.002) and general pain (p = 0.001). After 6 months,
the effect of TaTME disappeared for these scores, except
for social functioning (p = 0.013) and anal pain
(p = 0.013), which at 6 months remained significantly
lower than preoperative scores (Fig. 2).
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Bladder function
Symptoms of urinary incontinence, increased frequency or
dysuria did not change significantly after TaTME
(p = 0.425, p = 0.618 and p = 0.146, respectively). Mean
scores preoperatively were 3.7 (95% confidence interval
(CI) -0.5 to 7.9), 28.4 (95% CI 20.7–36.1), and 0.0 (95%
CI 0.0), respectively. The mean difference compared to
preoperative scores remained below 5.0 points at 1 and
6 months.
Ano(neo)rectal function after stoma closure
The mean preoperative LARS score was 15.4 (95% CI
7.3–23.5). At 1 month, this score significantly increased to
35.7 (95% CI 32.9–38.6), (p = 0.001). At 6 months, the
mean score fell to 21.7 (95% CI 13.6–29.9). The mean
difference between preoperative and 6-month values was
not significant (p = 0.339). A total of 33% of the included
patients reported symptoms correlating with major LARS
at 6 months. Descriptive values of LARS are shown in
Table 3.
Sexual function
Male interest in sexual intercourse significantly decreased
at 1 month postoperatively, but returned to the same level
as before surgery at 6 months. Erection problems did not
increase significantly after surgery (completion rate 57%).
Only two female patients answered the question about
sexual interest, and no female patient answered the ques-
tion about dyspareunia.
Discussion
To our knowledge, this is the first study to present preop-
erative and postoperative reported quality of life by
patients undergoing TaTME low anterior resection for
rectal cancer using prospectively gathered validated
Table 2 EQ-5D
Preoperative 1 month 6 months
EQ-5D index (mean, 95% CI)
p = 0.031¥
90.2 (83.9–96.5) 78.2 (68.9–87.4)
p = 0.0949
86.0 (79.9–92.2)
p = 0.8949
VAS (mean, 95% CI)
p = 0.002¥
82.5 (78.1–86.9) 70.0 (63.4–76.5)
p = 0.0089
77.5 (72.3–82.7)
p = 0.3519
Mobility
Level I 93 80 82
Level II 7 20 18
Level III 0 0 0
ADL
Level I 100 93 100
Level II 0 7 0
Level III 0 0 0
Social life
Level I 87 37 71
Level II 13 43 22
Level III 0 20 7
Experienced pain
Level I 77 47 63
Level II 23 47 37
Level III 0 6 0
Mood
Level I 77 83 78
Level II 20 17 22
Level III 3 0 0
All data in this table are presented as percentages unless explained otherwise
VAS visual analogue scale, CI confidence interval, ADL activities of daily life
¥ p value of repeated measures ANOVA
9 p = value of post hoc analysis performed when repeated measures ANOVA was significant
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questionnaires. One month after TaTME significantly
decreased, scores were reported for EQ-5D, EQ-VAS,
quality of life, physical functioning, role functioning, social
functioning, fatigue, general experienced pain, anal pain,
LARS, and male sexual interest. After 6 months, most
scores returned to baseline values except for social func-
tioning and anal pain, though mean values did improve.
Major LARS was present in 33% of the patients 6 months
after stoma reversal.
The study by Andersson et al. [19, 20] on health-related
quality of life using data from the COLOR II trial, one of
the largest randomized trials evaluating laparoscopic and
open rectal cancer resection, showed meaningful clinical
changes in quality of life at 1 month after conventional
rectal cancer surgery, but values returned to (or close to)
preoperative values by 6 months after surgery. These
results are comparable to the quality of life scores found in
our study using the same questionnaires (EQ-5D-3L and
EORTC QLQ-C30) and study design.
Major LARS is associated with an immense decrease in
quality of life [20] and is considered one of the most
important functional outcome measurements after rectal
surgery. Kneist et al. [12] were the first authors who
reported LARS after TaTME for low rectal cancer in 10
patients and showed that 40% of the patients experienced
no LARS, 50% minor LARS and only 10% major LARS
6 months after stoma closure. However, Pontallier et al.
[21] reported major LARS 12 months after stoma closure
in 82% of the patients with coloanal anastomosis. In our
study, the outcome of 15 patients showed 47% no LARS,
20% minor LARS and 33% major LARS. This percentage
for major LARS after TaTME in this study is lower than
the published scores found after conventional TME, which
are often reported around 50% [22–24]. This cohort
included 1 patient after anastomotic leakage who had an
adequate period of follow-up after reversal of the stoma.
Function of the other 3 patients with an anastomotic
leakage or presacral abscess is to be awaited and poten-
tially could negatively influence the LARS score found in
our cohort [25, 26]. On the other hand, our cohort ana-
lyzing anorectal function contains a high amount of
patients with an end-to-end anastomosis (73%), which is a
known risk factor for worse functional outcome on the
short term after rectal resection.
In our study, 3 patients (10%) developed urinary
retention postoperatively for which they needed temporary
catheterization. Patient-reported outcome on micturition
impairment at 4 weeks showed no significant increase,
which might imply good bladder function due to sparing of
the nerves. Our results after TaTME, describing urinary
retention requiring temporary catheterization in up to 10%
of patients, are comparable to those in the literature [8–12].
Permanent micturition problems, like incontinence, reten-
tion or increased voiding frequency have not been reported
after TaTME, as confirmed by the results of our study.
Decrease of sexual interest was observed at 1 month but
at 6 months this almost returned to preoperative values. No
significant erectile malfunction was seen compared to
baseline. Tuech and Kneist [11, 12] examined male sexual
function after TaTME and reported 11–22% impotence,
22% worse erectile function and 33% decreased ejacula-
tion. Pontallier et al. described laparoscopic surgery as an
independent risk factor for loss of sexual activity. No sig-
nificant difference was found in sexual function between
TaTME and laparoscopic TME [21].
Results on female patients after TaTME remain too
scarce to permit any solid conclusions. We included only
eight females and due to the low completion rate of the
questionnaires by these patients, valid statistical analysis
was not possible.
Four patients who underwent TaTME through APR
were excluded in order to minimize the heterogeneity of
0 
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EORTC QLQ-C29 & QLQ-CR30 
Before Surgery One month  
Six months 
Fig. 2 Domains measured by the EORTC QLQ-C29 and QLQ-CR30
questionnaires, at inclusion, and after 1 and 6 months. Mean scores
are shown. Only domains that changed significantly are displayed.
Asterisk significant difference at 6 months as compared to before
surgery. Multiplication sign a high value is positive to the patient;
dagger a high value is negative to the patient
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the study group. In the literature, the effects of a permanent
stoma on quality of life are a topic of debate. How et al.
and Kasparek et al. [27, 28] reported that this effect was not
significant and quality of life was similar between patients
who underwent low anterior resection and APR. Quality of
life after APR with distal extralevator or intersphincteric
transanal resection is still to be evaluated.
Our study results are obviously limited due to the small
sample size, great heterogeneity of the study group and
wide confidence intervals. Another limitation in this single-
center study is that no adequate comparison group could be
presented since all patients undergoing elective surgery for
mid- or low rectal cancer during the inclusion period were
operated on using TaTME. Therefore, this single-center
study provides exploratory findings rather than conclusive
evidence. Moreover, our follow-up was limited to
6 months since earlier studies evaluating health-related
quality of life after conventional surgery showed that
significant changes disappeared at 6 months after surgery
[18, 19]. The Wexner score, IPSS and IIEF-5 were not used
since most questions were already included in the ques-
tionnaires employed and in order to prevent a lower
response rate due to a larger number of questions asked at
the different time points. Only univariate analysis was
performed due to the small sample size; therefore, we were
not able to discriminate any potential risk factors for
decreased quality of life or impaired function including
type of anastomosis, anastomotic leakage, neoadjuvant
therapy or level of the anastomosis, factors which have
been observed to influence functional outcome after con-
ventional rectal resection [20, 25, 26, 29].
Despite these limitations, this study provides the first
data on quality of life and functional outcome at 1 and
6 months after TaTME compared to preoperative values
showing results comparable to published results after
laparoscopic abdominal TME. Extra focus on postoperative
Table 3 LARS
Before 1 month 6 months
Incontinence for flatus
Never 73.3 13.3 40.0
\Once a week 20.0 26.7 26.7
COnce a week 6.7 60.0 33.3
Incontinence for liquid stools
Never 80.0 26.7 40.0
\Once a week 13.3 33.3 26.7
C Once a week 6.7 40.0 33.3
Frequency bowel
1–3 times a day 46.7 26.7 26.7
4–7 times a day 20.0 40.0 46.7
[7 times a day 13.3 33.3 20.0
\Once a day 20.0 0 6.7
Clustering of stools
Never 53.3 0 26.7
\Once a week 20.0 13.3 33.3
COnce a week 26.7 86.7 40.0
Urgency
Never 53.3 0 46.7
\Once a week 13.3 20.0 26.7
COnce a week 33.3 80.0 26.7
LARS (mean, 95% CI)
p\ 0.001¥
15.4 (7.3–23.5) 35.7 (32.9–38.6)
p = 0.0019
21.7 (13.6–29.9)
p = 0.3399
No LARS 53.3 0 46.7
Minor LARS 33.3 20.0 20.0
Major LARS 13.4 80.0 33.3
All data in this table are presented as percentages unless explained otherwise
LARS low anterior resection syndrome, CI confidence interval
¥ p value of repeated measures ANOVA
9 p = value of post hoc analysis performed when repeated measures ANOVA was significant
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pain management and training of pelvic floor muscles
might be suggested to improve social functioning within
6 months after TaTME. The COLOR III trial, a random-
ized clinical trial comparing laparoscopic TME with
TaTME, will show robust data exploring quality of life,
functional results and all relevant parameters influencing
patient-reported outcome after mid- and low restorative
rectal cancer surgery [30].
Conclusions
Using validated questionnaires, TaTME does not appear to
substantially impair functional and quality of life outcomes
compared to laparoscopic abdominal TME. Further studies
are needed to confirm these results.
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